These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37272120)

  • 1. Bendamustine plus Rituximab versus R-miniCHOP: which is better for unfit patients with diffuse larger B-cell lymphoma?
    Zhang D; Dong Y; Zhang L
    J Chemother; 2024 Jul; 36(4):351-353. PubMed ID: 37272120
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman.
    Nakao S; Tanaka S; Abe K; Komiyama T; Sugiura Y; Nakaseko C; Shimizu N
    Intern Med; 2024 Jul; 63(13):1923-1927. PubMed ID: 37981304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of primary cardiac diffuse large B-cell lymphoma involving the coronary sinus with R-EPOCH: a case report and literature review.
    Rezvani A; Shah S
    Ann Hematol; 2024 Jul; 103(7):2557-2560. PubMed ID: 38748259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
    Li W; Chang Y; Liu X; Chen Z; Sun J; Geng Z; Zhang M; Zhang L
    Ann Hematol; 2024 Jun; 103(6):2003-2012. PubMed ID: 38308020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does R-EPOCH reduce the incidence of pulmonary embolism in cardiac lymphoma?
    Shiroshita K
    Ann Hematol; 2024 Sep; 103(9):3821. PubMed ID: 38990293
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy.
    Walter E; Schmitt T; Dietrich S; Ho A; Witzens-Harig M
    Leuk Lymphoma; 2012 Nov; 53(11):2290-2. PubMed ID: 22475324
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
    Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
    Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma.
    Cheng CL; Liu JH; Chou SC; Yao M; Tang JL; Tien HF
    Eur J Haematol; 2018 Jul; 101(1):28-37. PubMed ID: 29603428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
    Albertsson-Lindblad A; Palsdottir T; Smedby KE; Weibull CE; Glimelius I; Jerkeman M
    Haematologica; 2022 Mar; 107(3):740-743. PubMed ID: 34788983
    [No Abstract]   [Full Text] [Related]  

  • 13. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract]   [Full Text] [Related]  

  • 15. Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.
    Chan TS; Khong PL; Kwong YL
    Ann Hematol; 2016 Oct; 95(11):1917-8. PubMed ID: 27473194
    [No Abstract]   [Full Text] [Related]  

  • 16. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
    Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
    Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
    Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement.
    Kojima M; Amaki J; Ogiya D; Ando K; Nakamura N
    J Clin Exp Hematop; 2020 Jun; 60(2):60-61. PubMed ID: 32404573
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma.
    Hu X; Zeng M; Yang SE; Liang X; Ding SS; Guo L; Li S; Wen SJ
    Medicine (Baltimore); 2017 Nov; 96(45):e8494. PubMed ID: 29137041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.